StockWatch
·
Other Pharmaceuticals
DealsNov 16, 2026, 06:24 AM

DataMEDS AI Enters At-the-Market Sales Agreement with Dawson James Securities

AI Summary

DataMEDS AI, Inc. has entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. This agreement allows the company to offer and sell shares of its common stock from time to time through the sales agent. The sales will be conducted in accordance with Rule 415(a)(4) under the Securities Act, including sales on The Nasdaq Capital Market or other trading markets. DataMEDS AI will pay a 3.0% commission on the aggregate gross proceeds from sales and will reimburse the sales agent for certain expenses. The offering is being made pursuant to the company's effective shelf registration statement on Form S-3.

Key Highlights

  • DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc.
  • The agreement allows DataMEDS AI to offer and sell shares of its common stock up to a maximum amount.
  • Sales will be conducted through Dawson James Securities, Inc. as sales agent.
  • The company will pay a commission of 3.0% on aggregate gross proceeds from sales.
  • The offering is being made under the company's effective shelf registration statement on Form S-3.